101. Anti-SSA Ro52 and anti-Ro60 autoantibodies: association with clinical phenotypes.
- Author
-
Mazeda C, Oliveira N, Abreu C, Fraga V, Maduro I, Saraiva A, Inês L, Ferreira C, Correia AM, Nicolau R, Farinha F, Villanueva I, Jesus D, Abreu P, Neto A, Silva Dinis J, and Barcelos A
- Subjects
- Humans, Female, Male, Middle Aged, Cross-Sectional Studies, Aged, Autoantibodies blood, Adult, Connective Tissue Diseases immunology, Connective Tissue Diseases diagnosis, Connective Tissue Diseases blood, Biomarkers blood, Lupus Erythematosus, Systemic immunology, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic blood, RNA, Small Cytoplasmic immunology, Autoantigens, Phenotype, Ribonucleoproteins immunology, Antibodies, Antinuclear blood, Antibodies, Antinuclear immunology
- Abstract
Objectives: Anti-SSA autoantibodies can be differentiated according to their antigenic target proteins as anti-Ro60 (60 kDa) or anti-Ro52 (52 kDa). Anti-SSA(Ro60) antibodies are clearly associated with connective tissue diseases (CTD), but the clinical significance of anti-SSA(Ro52) antibodies remains unclear. The aim of the present study was to analyse the disease phenotype of patients with anti-Ro52 and/or anti-Ro60 antibodies., Methods: A multicentre, cross-sectional study was carried out of positive anti-Ro52 and/or Ro60 antibodies patients followed at 10 Rheumatology centres from January 2018 until December 2021. Patients were categorised into 3 groups: group 1 (Ro52+/Ro60-); group 2 (Ro52-/Ro60+); group 3 (Ro52+/Ro60+). Antinuclear antibodies were evaluated by indirect immunofluorescence assay and further screened for anti-extractable nuclear antigen (ENA) antibodies. Demographicsand clinical data were compared between the 3 groups, by patients' medical chart review. Univariate analysis was performed and subsequently logistic regression was used to identify intergroup differences and calculate the odds ratio with a 95% confidence interval (95% CI)., Results: We included 776 patients [female: 83.1%; median age: 59 (46-71) years]. Groups 1, 2, and 3 comprised 31.1%, 32.6%, and 36.3% of the patients, respectively. Anti-Ro52 antibody alone was more frequently associated with non-rheumatic diseases, older age, and men (p<0.05). Among patients with CTD, the diagnosis of systemic lupus erythematosus is 3 and 2 times more prevalent in groups 2 and 3, respectively, than in group 1 [OR 2.8 (95% CI 1.60, 4.97), p<0.001; OR 2.2 (95% CI 1.28, 3.86), p<0.01]. In group 2, the diagnosis of undifferentiated CTD is more frequent than in the other groups. Group 1 was more frequently associated with inflammatory myositis than group 2 [OR 0.09 (95% CI 0.01, 0.33), p<0.001] or group 3 [OR 0.08 (95% CI 0.01, 0.29), p<0.001]. Group 1 was also more frequently associated with arthritis (p<0.01), interstitial lung disease (p<0.01), and myositis (p<0.01)., Conclusions: Anti-Ro52+ antibody alone is frequently found in patients with non-rheumatic diseases. In addition, anti-Ro52+ antibody is also prevalent in patients with CTD and associated with clinical phenotypes that are different from anti-Ro60+ antibody.
- Published
- 2024
- Full Text
- View/download PDF